1 pt had grade 5 toxicity (aortic fistula), from re-RT. Conclusions: In the first prospective trial of PBT re-RT + consolidation pembro, treatment proved feasible and PFS was acceptable though the capacity to administer pembro was limited. This approach may be considered in selected patients ...
Trial design Pts will be randomly assigned 1:1 to two arms. In arm A, pts will receive neoadjuvant pembro (200 mg Q3W, 2 cycles), followed by surgical resection, then SOC plus adjuvant pembro (200 mg Q3W, 15 cycles). In arm B, pts will undergo surgical resection followed by adju...
Clinical trial identification NCT02775435, NCT03875092. Editorial acknowledgement Vidya Ramachandran, PhD, of C4 MedSolutions, LLC (Yardley, PA, USA), a CHC Group company, and funded by Merck Sharp & Dohme Corp., a subsidiary of ...
Clinical trial information: NCT03407144.doi:10.1200/JCO.2023.41.16_suppl.10027Luciana VintiStephen DawConstantino Sabado AlvarezFranca FagioliAuke BeishuizenGérard MichelMaria Luisa MoletiMichaela CepelovaAnne ThorwarthCharlotte RigaudAmerican Society of Clinical OncologyJournal of Clinical Oncology...